Risk factors for severe pulmonary and disseminated coccidioidomycosis: Kern County, California, 1995-1996

被引:156
作者
Rosenstein, NE
Emery, KW
Werner, SB
Kao, A
Johnson, R
Rogers, D
Vugia, D
Reingold, A
Talbot, R
Plikaytis, BD
Perkins, BA
Hajjeh, RA
机构
[1] Ctr Dis Control & Prevent, Biostat & Informat Management Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA
[2] Ctr Dis Control & Prevent, Meningitis & Special Pathogens Branch, Atlanta, GA 30333 USA
[3] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30333 USA
[4] Calif Dept Hlth Serv, Berkeley, CA 94704 USA
[5] Univ Calif Berkeley, Berkeley, CA USA
[6] Kern Cty Hlth Dept, Bakersfield, CA USA
[7] Kern Med Ctr, Bakersfield, CA USA
[8] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
关键词
D O I
10.1086/319203
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Surveillance for coccidioidomycosis (CM) and a case-control study for risk factors among adults were conducted in Kern County, California. From January 1995 through December 1996, 905 cases of CM were identified, for an annual incidence of 86 cases per 100,000 population. A total of 380 adults were enrolled in the case-control study: 77 had severe pulmonary disease, 33 had disseminated disease, and 270 control patients had mild disease. Independent risk factors for severe pulmonary disease included diabetes, recent history of cigarette smoking, income of <$ 15,000 per year, and older age. Oral antifungal therapy before hospitalization was associated with a reduced risk of CM pneumonia. Risk factors for disseminated disease were black race, income of <$ 15,000 per year, and pregnancy. Early treatment of CM with oral antifungal agents may prevent severe pulmonary disease in groups considered to be at high risk, such as elderly individuals, persons with diabetes, and smokers. Persons at risk for severe CM may benefit from vaccination once an effective CM vaccine is available.
引用
收藏
页码:708 / 714
页数:7
相关论文
共 32 条
[1]   In vitro modulation of proliferation and cytokine production by human peripheral blood mononuclear cells from subjects with various forms of coccidioidomycosis [J].
Ampel, NM ;
Christian, L .
INFECTION AND IMMUNITY, 1997, 65 (11) :4483-4487
[2]   Coccidioidomycosis in Arizona: Increase in incidence from 1990 to 1995 [J].
Ampel, NM ;
Mosley, DG ;
England, B ;
Vertz, PD ;
Komatsu, K ;
Hajjeh, RA .
CLINICAL INFECTIOUS DISEASES, 1998, 27 (06) :1528-1530
[3]  
[Anonymous], 1997, MMWR Recomm Rep, V46, P1
[4]  
[Anonymous], 1995, VALLEY FEVER TASK FO
[5]  
[Anonymous], 1937, CAL W MED
[6]  
Caldwell JW, 1996, COCCIDIOIDOMYCOSIS, P275
[7]   AN EVALUATION OF REACTIVITY TO COCCIDIOIDES-IMMITIS SKIN-TESTS IN SUBJECTS WITH DIABETES-MELLITUS [J].
CAMPBELL, SC ;
SMITH, JP .
MYCOPATHOLOGIA, 1982, 80 (03) :133-136
[8]  
*CDCP, 1994, MMWR-MORBID MORTAL W, V43, P421
[9]  
Centers for Disease Control and Prevention, 1996, MMWR MORB MORTAL WKL, V45, P1069
[10]  
DRUTZ DJ, 1978, AM REV RESPIR DIS, V117, P559